Open access
Interim BNT162b2 LP.8.1-adapted COVID-19 Vaccine Effectiveness among Non-Immunocompromised Older Adults in California and Louisiana, August-December 2025
L. Zambrano
T. Yu
J. Mateus
X. Zhao
K. Andersen
S. Valluri
B. Karakuzu Ikizler
R. Nepal
A. J. MacNeil
H. Volkman
Medicine
Abstract
Evidence on vaccine effectiveness (VE) of 2025-26 COVID-19 vaccines is limited. We estimated VE of BNT162b2 LP.8.1-adapted vaccine among non-immunocompromised adults [≥]65 years through December 2025 using linked claims and immunization registry data from two U.S. states. VE against COVID-19-related ED/UC encounters was 48% (95% CI:19, 66).